Overview of embryonal rhabdomyosarcoma of cervix in women over 40-year-old

作     者：Malala Razakanaivo Nam P Nguyen Juliette Thariat Vincent Molinie Anne-Therese Vlastos Claire Verschraegen Vincent Vinh-Hung 

作者机构：Joseph Ravoahangy Andrianavalona University Hospital Radiation OncologyHoward University Hospital International Geriatric Radiotherapy Group Antoine-Lacassagne Cancer CenterUniversity Nice Sophia Antipolis Rare Cancer Network Department of PathologyUniversity Hospital of Martinique Geneva Gynecology and Obstetrics Division of Hematology OncologyUniversity of Vermont Cancer Center Radiation OncologyUniversity Hospital of Martinique Radiotherapy DepartmentUZ BrusselVrije Universiteit Brussel 

出 版 物：《World Journal of Obstetrics and Gynecology》 (世界妇产科杂志)

年 卷 期：2016年第5卷第1期

页      面：110-117页

学科分类：1002[医学-临床医学] 100211[医学-妇产科学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Embryonal rhabdomyosarcoma Botryoid sarcoma Cervix Middle-aged adults Chemotherapy Radiotherapy Review 

摘      要：The literature on cervical embryonal rhabdomyosarcoma(RMS) is reviewed here to identify management guidelines for middle-aged women diagnosed with this rare type of gynecologic cancer. Specifically, the Pub Med, Web of Science and Google Scholar databases, were searched to find published case series on cervical embryonal RMS reporting on four or more patients, of whom at least one was 40-year-old. The χ2 test was used to assess heterogeneity. Five articles published between 1986 and 2013 were identified, reporting on a total of 47 patients, of whom 22(46.8%) were older and 25(53.2%) younger than 40-year-old. Although the two age groups did not differ significantly by stage of disease or radiotherapy treatment, the older age groupreceived less chemotherapy(55% vs 90%, P = 0.008)and had more hysterectomy(86% vs 43%, P = 0.009).Follow-up data was missing for 18/47(38.3%) *** the 29 patients with follow-up data, survival was shorter in the older group, with 8/12(67%) alive and3 with disease at a median follow-up of 2.6 years, as compared with the younger group that had 15/17(88%)alive and none with disease at a median follow-up of 3.5years. The longest survivals among the older women were observed in those who received radiotherapy,including one case with a resected lung metastasis.A prospective multi-institutional collaboration and better follow-up are needed to determine the optimal management of cervical embryonal RMS. Long-term survival appears feasible if management is accompanied by chemotherapy and radiotherapy.